(Hypertension. 1999;34:171-175.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From St Vincent's Institute of Medical Research, Victoria, Australia.
Correspondence to Dr DJ Campbell, St Vincent's Institute of Medical Research, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia. E-mail j.campbell{at}medicine.unimelb.edu.au
AbstractAngiotensin-converting enzyme (ACE) converts angiotensin I (Ang I) to angiotensin II (Ang II) and metabolizes bradykinin and kallidin peptides. Decreased Ang II levels and increased kinin peptide levels are implicated in the mediation of the therapeutic effects of ACE inhibition. However, alternative non-ACE pathways of Ang II formation have been proposed to predominate in human heart. We investigated the effects of ACE inhibition on cardiac tissue levels of angiotensin and kinin peptides. High-performance liquid chromatographybased radioimmunoassays were used to measure angiotensin peptides and hydroxylated and nonhydroxylated bradykinin and kallidin peptides in right atrial appendages of subjects who had been prepared for cardiopulmonary bypass. Peptide levels in subjects who received ACE inhibitor therapy were compared with those who did not receive ACE inhibitor therapy. ACE inhibition reduced Ang II levels, which was associated with an 80% reduction in the Ang II/Ang I ratio. ACE inhibition did not modify either bradykinin or kallidin peptide levels or the bradykinin-(1-7)/bradykinin-(1-9) ratio. The 80% reduction in the Ang II/Ang I ratio by ACE inhibition indicated a primary role for ACE in the conversion of Ang I to Ang II in atrial tissue. These data support a role for reduced Ang II levels but do not support a role for increased kinin peptide levels in mediating the direct cardiac effects of ACE inhibition.
Key Words: angiotensin bradykinin kallidin angiotensin-converting enzyme heart
This article has been cited by other articles:
![]() |
L. Rosivall and J. Peti-Peterdi Heterogeneity of the afferent arteriole--correlations between morphology and function Nephrol. Dial. Transplant., November 1, 2006; 21(11): 3346 - 3346. [Full Text] [PDF] |
||||
![]() |
K. B. Brosnihan, L. A.A. Neves, and M. C. Chappell Does the Angiotensin-Converting Enzyme (ACE)/ACE2 Balance Contribute to the Fate of Angiotensin Peptides in Programmed Hypertension? Hypertension, November 1, 2005; 46(5): 1097 - 1099. [Full Text] [PDF] |
||||
![]() |
D. J. Campbell, T. Alexiou, H. D. Xiao, S. Fuchs, M. J. McKinley, P. Corvol, and K. E. Bernstein Effect of Reduced Angiotensin-Converting Enzyme Gene Expression and Angiotensin-Converting Enzyme Inhibition on Angiotensin and Bradykinin Peptide Levels in Mice Hypertension, April 1, 2004; 43(4): 854 - 859. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Campbell, B. Dixon, A. Kladis, M. Kemme, and J. D. Santamaria Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2001; 281(4): R1059 - R1070. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Tom, R. de Vries, P. R. Saxena, and A.H. J. Danser Bradykinin Potentiation by Angiotensin-(1-7) and ACE Inhibitors Correlates With ACE C- and N-Domain Blockade Hypertension, July 1, 2001; 38(1): 95 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Duncan, A. Kladis, G. L. Jennings, A. M. Dart, M. Esler, and D. J. Campbell Kinins in humans Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2000; 278(4): R897 - R904. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |